The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer.

ABSTRACT: Immunotherapy has led to a paradigm shift in the treatment of several cancers. There have been significant efforts to identify biomarkers that can predict response and toxicities related to immune checkpoint inhibitor (ICPI) therapy. Despite these advances, it has been challenging to tease out why a subset of patients benefit more than others or why certain patients experience immune-related adverse events (irAEs). Although the immune-modulating properties of the human gut bacterial ecosystem are yet to be fully elucidated, there has been growing interest in evaluating the role of the gut microbiome in shaping the therapeutic response to cancer immunotherapy. Considerable research efforts are currently directed to utilizing metagenomic and metabolic profiling of stool microbiota in patient

SUBMITTER: Naqash AR 

PROVIDER: S-EPMC8267312 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature